Insulet Corporation (NASDAQ:PODD) was upgraded by research analysts at Canaccord Genuity from a “hold” rating to a “buy” rating in a report issued on Wednesday.

Several other brokerages have also issued reports on PODD. Robert W. Baird set a $65.00 price target on Insulet Corporation and gave the company a “buy” rating in a research note on Friday, October 13th. Zacks Investment Research raised Insulet Corporation from a “sell” rating to a “hold” rating and set a $68.00 price target on the stock in a research note on Thursday, October 12th. Leerink Swann reissued an “outperform” rating and issued a $74.00 price target (up from $65.00) on shares of Insulet Corporation in a research note on Thursday, October 12th. Barclays PLC assumed coverage on Insulet Corporation in a research note on Friday, September 15th. They issued an “overweight” rating and a $65.00 price target on the stock. Finally, Wedbush reissued a “buy” rating and issued a $65.00 price target (up from $60.00) on shares of Insulet Corporation in a research note on Tuesday, October 10th. Eight research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Insulet Corporation presently has an average rating of “Buy” and an average price target of $56.36.

Insulet Corporation (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported ($0.04) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.06. The company had revenue of $121.80 million for the quarter, compared to analyst estimates of $114.02 million. Insulet Corporation had a negative return on equity of 46.74% and a negative net margin of 7.30%. The firm’s quarterly revenue was up 28.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.05) earnings per share.

ILLEGAL ACTIVITY NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2017/11/01/canaccord-genuity-reiterates-hold-rating-for-insulet-corporation-podd.html.

In other news, EVP Charles Alpuche bought 2,500 shares of the stock in a transaction dated Wednesday, September 6th. The shares were bought at an average cost of $58.08 per share, with a total value of $145,200.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.90% of the stock is owned by corporate insiders.

Large investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Insulet Corporation by 11.4% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,302 shares of the medical instruments supplier’s stock worth $118,000 after buying an additional 235 shares in the last quarter. SG Americas Securities LLC bought a new stake in Insulet Corporation during the second quarter worth $180,000. Diversified Trust Co bought a new stake in Insulet Corporation during the second quarter worth $205,000. Wrapmanager Inc. bought a new stake in Insulet Corporation during the second quarter worth $217,000. Finally, RNC Capital Management LLC bought a new stake in Insulet Corporation during the second quarter worth $225,000.

About Insulet Corporation

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Analyst Recommendations for Insulet Corporation (NASDAQ:PODD)

Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.